Here, in 36 patients with RCC followed up over a median of 4.2 years with a systematic xenograft of their primary tumor, we compared p53-expressing cells in tissue samples of the primary RCCs, their corresponding metastases when available, and the xenografts if the engraftment was successful. The gene discussed is TP53; the disease is renal cell carcinoma.